In recent years, the study of neurodegenerative diseases has accomplished the development of a Medicinal Chemistry oriented strategy towards the design, synthesis and pharmacological study of a large number of compounds with central dopaminergic activity, but, has not found yet a drug capable to effectively cure these diseases. It is well known that both in Venezuela and particular in the Zulia region of this country, there is a high incidence of neurodegenerative and psychiatric disorders, such as Parkinson's, schizophrenia, mania, depression, tardive dyskinesia diseases, Tourette's disease, drug addiction and eating disorders. This has motivated us to direct our research into this important health area, in the search of a rational development of new drugs. This paper describes the design of analogs of N-[(2-chloro-quinoline)-3-yl-methyl]-4,5-dimethoxy-2-aminoindan hydrochloride (9) and the N-[(2-chloro-7-methyl-quinolin )-3-yl-methyl)]- 4,5-dimethoxy-2-aminoindan hydrochloride (10) as novel agents to counteract some of these pathologies. Their convergent organic synthesis was performed according to the synthetic strategies proposed, and the spectroscopic elucidation of the final products was made by NMR techniques 1H, 13C, DEPT, HETCOR and COSY, confirming their structures. The preliminary pharmacological evaluation in stereotypic behavior, demonstrates their agonistic activities on the central dopaminergic system, validating a ready-witted medicinal chemistry approach in the design of these click type drugs.